Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Change in composition of the Board of the Company

Emcure Ref: EPL/CS/SE/0067/2026 Date: August 06, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Change in composition of the Board of the Company Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘SEBI Listing Regulations’) and based on the recommendation of the Nomination and Remuneration Committee, we hereby inform you that the Board of Directors of the Company at their meeting held today i.e. Thursday, August 06, 2026, has noted/ approved the following: 1. Mr. Berjis Desai (DIN: 00153675) Chairman and Non-executive, Non-Independent Director, who is liable to retire by rotation at the ensuing Annual General Meeting (“AGM”) of the Company, has expressed his unwillingness to seek re-appointment, due to his appointment as a member of the National Commission for Minorities, New Delhi. Consequently, Mr. Berjis Desai shall cease to hold office as a Chairman and Director of the Company and the existing Committee positions held by him, with effect from the conclusion of the ensuing AGM. 2. Appointment of Mr. Raghu Kumar (DIN: 01983106) as an Additional Director (Non-Executive and Independent) of the Company with effect from August 06, 2026 and as an Independent Director for first term of three (3) consecutive years, with effect from August 06, 2026, subject to approval of Members of the Company. Mr. Raghu Kumar is not debarred from holding the office of a Director by virtue of any Securities and Exchange Board of India (‘SEBI’) order and in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018, or any such other authority, and he is not related to any Director(s) or Key Managerial Personnel(s) of the Company. Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure 3. Appointment of Mr. Satish Mehta (DIN: 00118691), Managing Director CEO as the Chairman of the Company, with effect from the conclusion of the ensuing AGM, in view of the retirement of Mr. Berjis Desai (DIN: 00153675), Chairman and Non-Executive, Non- Independent Director of the Company. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are enclosed herewith as Annexure. You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer ICSI Membership No.: A25687 Encl.: As above Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure Annexure Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015: Sr. Particulars Information Mr. Berjis Desai Mr. Raghu Kumar Mr. Satish Mehta 1 Reason for change Mr. Berjis Desai A p p o i n t m ent of M r . S atish Mehta (DIN: viz. appointment re- (DIN: 00153675) Mr. Raghu Kumar (DIN: 00118691), Managing appointment, Chairman and 0 1 9 8 3 1 0 6 ) as an Director & CEO as the resignation, Non-executive, Additional Director Chairman of the Company removal, death or Non-Independent (Non-Executive with effect from the otherwise Director who is liable to and Independent) with conclusion of the ensuing retire by rotation at the effect from A G M . ensuing Annual General August 06, 2026 and as an Meeting (“AGM”) of the Independent Director of Company, has expressed the Company with effect his unwillingness to seek from August 06, 2026. re-appointment. Consequently, Mr. Berjis Desai shall cease to hold office as a Chairman and Director of the Company, with effect from the conclusion of the AGM. 2 Date of On conclusion of the Appointment as an With effect from the appointment/ e n s u i n g AGM, i.e., Additional Director conclusion of the ensuing re-appointment/ September 21, 2026 (Non-Executive AGM i.e., cessation and Independent) with September 21, 2026 (as applicable) effect from August 06, 2026 and as an Independent Director for first term of three (3) consecutive years, with effect from August 06, 2026, subject to approval of Members of the Company in the ensuing AGM, i.e., September 21, 2026. 3 Brief profile Not Applicable Mr. Raghu Kumar has Mr. Satish Mehta, (in case of over four decades of Managing Director & CEO appointment); experience in the started Emcure in 1981 with pharmaceutical, the purpose to provide healthcare and consumer affordable and high quality products sectors. He has healthcare to patients to held various senior significantly improve their leadership positions lives and is the prime across leading mover for growth plans of multinational the company. organizations, including Allergan, Novartis and Under his leadership, Bayer, and has extensive Emcure has become a well- Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure experience in business respected name in the transformation, strategic global pharma market with growth, operational its presence in more than 70 excellence and talent countries through its development. He subsidiaries in UK, Canada, currently serves as the Singapore, Brazil and other Chairman and countries. Independent Director of Emcutix With his continued Biopharmaceuticals guidance and leadership, Limited, a wholly owned Emcure continues its subsidiary of Emcure upward trend and goal of Pharmaceuticals Limited. providing effective medicines at affordable Mr. Raghu Kumar holds a prices along with having a Bachelor's Degree broader impact on the (Honours) in Economics society. and Mathematics from St. Stephen's College, University of Delhi, and a Post Graduate Degree in Business Management (Marketing) from the Indian Institute of Management, Ahmedabad. 4 Disclosure of Not Applicable Mr. Raghu Kumar is not Mr. Satish Mehta is father relationships related to any Director of of Mr. Samit Mehta and between Directors the Company. Mrs. Namita Thapar, (in case of Whole-time Directors of the appointment of a Company. director). Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251